Clinical studiesRandomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease☆
Under an Elsevier user license
open archive
Abbreviations
ACE
angiotensin-converting enzyme
BP
blood pressure
CHF
congestive heart failure
HOPE
Heart Outcomes Prevention Evaluation
LV
left ventricle (left ventricular)
MI
myocardial infarction
TIA
transient ischemic attack
Cited by (0)
- ☆
The Prevention of Atherosclerosis with Ramipril (PART 2) trial was supported by a project grant from Hoechst AG, the manufacturers of ramipril and by a program grant from the Health Research Council of New Zealand.
Copyright © 2000 American College of Cardiology. Published by Elsevier Inc. All rights reserved.